Form 4: Supernus Pharmaceuticals SVP & CFO Timothy Dec Reports Stock Transactions
SEC Form 4 Filing
Timothy C. Dec, Senior Vice President & CFO of Supernus Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units.
Summary
- On February 22, 2025, Timothy C. Dec acquired 500 shares of common stock and disposed of 500 restricted stock units.
- On the same day, he acquired 3,000 shares of common stock and disposed of 3,000 restricted stock units.
- On February 23, 2025, he acquired 2,500 shares of common stock and disposed of 2,500 restricted stock units.
- Following these transactions, Dec beneficially owns 14,091 shares of common stock and 5,000 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing, so the sentiment is neither positive nor negative.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership of shares.
Key Dates
| Date | Description |
|---|---|
| 02/22/2023 | Vesting start date for some restricted stock units. |
| 02/23/2024 | Vesting start date for some restricted stock units. |
| 02/22/2025 | Date of common stock and restricted stock unit transactions. |
| 02/23/2025 | Date of common stock and restricted stock unit transactions. |
| 02/24/2025 | Date of signature. |
Keywords
Supernus Pharmaceuticals, Timothy C. Dec, Form 4, Stock Transactions, Restricted Stock Units, Common Stock, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.